Literature DB >> 32637645

Incidence and predictors of early seizures in intracerebral haemorrhage and the effect of tranexamic acid.

Zhe Kang Law1,2, Timothy J England1,3, Amit K Mistri4, Lisa J Woodhouse1, Lesley Cala5, Rob Dineen6,7, Serefnur Ozturk8, Maia Beridze9, Ronan Collins10, Philip M Bath1,11, Nikola Sprigg1,11.   

Abstract

INTRODUCTION: Seizures are common after intracerebral haemorrhage. Tranexamic acid increases the risk of seizures in non-intracerebral haemorrhage population but its effect on post-intracerebral haemorrhage seizures is unknown. We explored the risk factors and outcomes of seizures after intracerebral haemorrhage and if tranexamic acid increased the risk of seizures in the Tranexamic acid for IntraCerebral Haemorrhage-2 trial. PATIENTS AND METHODS: Seizures were reported prospectively up to day 90. Cox regression analyses were used to determine the predictors of seizures within 90 days and early seizures (≤7 days). We explored the effect of early seizures on day 90 outcomes.
RESULTS: Of 2325 patients recruited, 193 (8.3%) had seizures including 163 (84.5%) early seizures and 30 (15.5%) late seizures (>7 days). Younger age (adjusted hazard ratio (aHR) 0.98 per year increase, 95% confidence interval (CI) 0.97-0.99; p = 0.008), lobar haematoma (aHR 5.84, 95%CI 3.58-9.52; p < 0.001), higher National Institute of Health Stroke Scale (aHR 1.03, 95%CI 1.01-1.06; p = 0.014) and previous stroke (aHR 1.66, 95%CI 1.11-2.47; p = 0.013) were associated with early seizures. Tranexamic acid did not increase the risk of seizure within 90 days. Early seizures were associated with worse modified Rankin Scale (adjusted odds ratio (aOR) 1.79, 95%CI 1.12-2.86, p = 0.015) and increased risk of death (aOR 3.26, 95%CI 1.98-5.39; p < 0.001) at day 90.Discussion and conclusion: Lobar haematoma was the strongest independent predictor of early seizures after intracerebral haemorrhage. Tranexamic acid did not increase the risk of post-intracerebral haemorrhage seizures in the first 90 days. Early seizures resulted in worse functional outcome and increased risk of death. © European Stroke Organisation 2020.

Entities:  

Keywords:  Seizures; incidence; intracerebral haemorrhage; randomised controlled trial; tranexamic acid

Year:  2020        PMID: 32637645      PMCID: PMC7313371          DOI: 10.1177/2396987320901391

Source DB:  PubMed          Journal:  Eur Stroke J        ISSN: 2396-9873


  28 in total

1.  Tranexamic acid, a widely used antifibrinolytic agent, causes convulsions by a gamma-aminobutyric acid(A) receptor antagonistic effect.

Authors:  Roman Furtmüller; Michael G Schlag; Michael Berger; Rudolf Hopf; Sigismund Huck; Werner Sieghart; Heinz Redl
Journal:  J Pharmacol Exp Ther       Date:  2002-04       Impact factor: 4.030

2.  Seizures After Intracerebral Hemorrhage: Incidence, Risk Factors, and Impact on Mortality and Morbidity.

Authors:  Amol Mehta; Benjamin E Zusman; Ravi Choxi; Lori A Shutter; Ahmed Yassin; Arun Antony; Parthasarathy D Thirumala
Journal:  World Neurosurg       Date:  2018-01-31       Impact factor: 2.104

3.  Electrographic seizures and periodic discharges after intracerebral hemorrhage.

Authors:  J Claassen; N Jetté; F Chum; R Green; M Schmidt; H Choi; J Jirsch; J A Frontera; E Sander Connolly; R G Emerson; S A Mayer; L J Hirsch
Journal:  Neurology       Date:  2007-09-25       Impact factor: 9.910

Review 4.  Recommendation for a definition of acute symptomatic seizure.

Authors:  Ettore Beghi; Arturo Carpio; Lars Forsgren; Dale C Hesdorffer; Kristina Malmgren; Josemir W Sander; Torbjorn Tomson; W Allen Hauser
Journal:  Epilepsia       Date:  2009-09-03       Impact factor: 5.864

5.  Do Early Seizures Indicate Survival of Patients with Nontraumatic Intracerebral Hemorrhage?

Authors:  Toralf Brüning; Samer Awwad; Mohamed Al-Khaled
Journal:  Cerebrovasc Dis       Date:  2015-12-16       Impact factor: 2.762

6.  Incidence of seizures in the acute phase of stroke: a population-based study.

Authors:  Jerzy P Szaflarski; Angela Y Rackley; Dawn O Kleindorfer; Jane Khoury; Daniel Woo; Rosemary Miller; Kathleen Alwell; Joseph P Broderick; Brett M Kissela
Journal:  Epilepsia       Date:  2008-01-31       Impact factor: 5.864

7.  Intravenous tranexamic acid for hyperacute primary intracerebral hemorrhage: Protocol for a randomized, placebo-controlled trial.

Authors:  Nikola Sprigg; Katie Robson; Philip Bath; Robert Dineen; Ian Roberts; Tom Robinson; Christine Roffe; David Werring; Rustam Al-Shahi Salman; Stuart Pocock; Lelia Duley; Tim England; David Whynes; Alfonso Ciccone; Ann Charlotte Laska; Hanne Christensen; Serefnur Ozturk; Ronan Collins; Daniel Bereczki; Juan Jose Egea-Guerrero; Zhe Kang Law; Anna Czlonkowska; David Seiffge; Maia Beredzie
Journal:  Int J Stroke       Date:  2016-04-05       Impact factor: 5.266

8.  Tranexamic acid concentrations associated with human seizures inhibit glycine receptors.

Authors:  Irene Lecker; Dian-Shi Wang; Alexander D Romaschin; Mark Peterson; C David Mazer; Beverley A Orser
Journal:  J Clin Invest       Date:  2012-11-26       Impact factor: 14.808

9.  Seizures after spontaneous intracerebral hemorrhage.

Authors:  Kwang-Moo Woo; Seung-Yeob Yang; Keun-Tae Cho
Journal:  J Korean Neurosurg Soc       Date:  2012-10-22

10.  Early seizures in patients with acute stroke: frequency, predictive factors, and effect on clinical outcome.

Authors:  Andrea Alberti; Maurizio Paciaroni; Valeria Caso; Michele Venti; Francesco Palmerini; Giancarlo Agnelli
Journal:  Vasc Health Risk Manag       Date:  2008
View more
  2 in total

1.  Seizures and epilepsy after intracerebral hemorrhage: an update.

Authors:  Laurent Derex; Sylvain Rheims; Laure Peter-Derex
Journal:  J Neurol       Date:  2021-02-10       Impact factor: 4.849

2.  Relationship Between Mortality and Seizures After Intracerebral Hemorrhage: A Systematic Review and Meta-Analysis.

Authors:  Hong-Yu Lin; Qing-Qing Wei; Jian-Yi Huang; Xing-Hua Pan; Ning-Chao Liang; Cai-Xia Huang; Teng Long; Wen Gao; Sheng-Liang Shi
Journal:  Front Neurol       Date:  2022-06-20       Impact factor: 4.086

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.